SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice

FASEB Journal

Volumn 26, Issue 8, 2012, Pages 3282-3291

  Zadjali, Fahad ^a,b,c   Santana Farre, Ruyman ^d   Vesterlund, Mattias ^a,b   Carow, Berit ^b   Mirecki Garrido, Mercedes ^d   Hernandez Hernandez, Irene ^e,f   Flodström Tullberg, Malin ^b   Parini, Paolo ^b   Rottenberg, Martin ^b   Norstedt, Gunnar ^b   Fernandez Perez, Leandro ^d   Flores Morales, Amilcar ^a  

^a University of Copenhagen   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SULTAN QABOOS UNIVERSITY   (Oman)

^d Madrid Spain   (Spain)

^e UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^f INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Growth hormone; Inflammation; Suppressor of cytokine signaling

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; SUPPRESSOR OF CYTOKINE SIGNALING 2; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FATTY LIVER; GENE DELETION; GENE EXPRESSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID LIVER LEVEL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DIET, HIGH-FAT; FATTY LIVER; INSULIN RESISTANCE; INTERFERON-GAMMA; INTERLEUKIN-6; LIPID METABOLISM; LIVER; MALE; MICE; MICE, KNOCKOUT; NF-KAPPA B; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TOLL-LIKE RECEPTOR 4; TRIGLYCERIDES;

MUS;

EID: 84864665833     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-205583     Document Type: Article

References (34)

1. Zhang, D., Christianson, J., Liu, Z. X., Tian, L., Choi, C. S., Neschen, S., Dong, J., Wood, P. A., and Shulman, G. I. (2010) Resistance to high-fat diet-induced obesity and insulin resistance in mice with very long-chain acyl-CoA dehydrogenase deficiency. Cell Metab. 11, 402-411
2. Kodama, Y., Kisseleva, T., Iwaisako, K., Miura, K., Taura, K., De Minicis, S., Osterreicher, C. H., Schnabl, B., Seki, E., and Brenner, D. A. (2009) c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 137, 1467-1477+e1465
3. Saberi, M., Woods, N. B., de Luca, C., Schenk, S., Lu, J. C., Bandyopadhyay, G., Verma, I. M., and Olefsky, J. M. (2009) Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fatfed mice. Cell Metab. 10, 419-429
4. Rico-Bautista, E., Flores-Morales, A., and Fernandez-Perez, L. (2006) Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev. 17, 431-439 (Pubitemid 44793121)
5. Wormald, S., Zhang, J. G., Krebs, D. L., Mielke, L. A., Silver, J., Alexander, W. S., Speed, T. P., Nicola, N. A., and Hilton, D. J. (2006) The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J. Biol. Chem. 281, 11135-11143 (Pubitemid 43855538)
6. Lang, R., Pauleau, A. L., Parganas, E., Takahashi, Y., Mages, J., Ihle, J. N., Rutschman, R., and Murray, P. J. (2003) SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4, 546-550 (Pubitemid 36701337)
7. Rui, L., Yuan, M., Frantz, D., Shoelson, S., and White, M. F. (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277, 42394-42398 (Pubitemid 35257562)
8. Ueki, K., Kondo, T., Tseng, Y. H., and Kahn, C. R. (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. U. S. A. 101, 10422-10427 (Pubitemid 38924941)
9. Sachithanandan, N., Fam, B. C., Fynch, S., Dzamko, N., Watt, M. J., Wormald, S., Honeyman, J., Galic, S., Proietto, J., Andrikopoulos, S., Hevener, A. L., Kay, T. W., and Steinberg, G. R. (2010) Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity. Hepatology 52, 1632-1642
10. Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., Kay, T. W., Nicola, N. A., Hertzog, P. J., Metcalf, D., and Hilton, D. J. (1999) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597-608 (Pubitemid 29418951)
11. Elam, M. B., Cowan, G. S., Jr., Rooney, R. J., Hiler, M. L., Yellaturu, C. R., Deng, X., Howell, G. E., Park, E. A., Gerling, I. C., Patel, D., Corton, J. C., Cagen, L. M., Wilcox, H. G., Gandhi, M., Bahr, M. H., Allan, M. C., Wodi, L. A., Cook, G. A., Hughes, T. A., and Raghow, R. (2009) Hepatic gene expression in morbidly obese women: implications for disease susceptibility. Obesity 17, 1563-1573
12. Greenhalgh, C. J., Rico-Bautista, E., Lorentzon, M., Thaus, A. L., Morgan, P. O., Willson, T. A., Zervoudakis, P., Metcalf, D., Street, I., Nicola, N. A., Nash, A. D., Fabri, L. J., Norstedt, G., Ohlsson, C., Flores-Morales, A., Alexander, W. S., and Hilton, D. J. (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J. Clin. Invest. 115, 397-406 (Pubitemid 40385481)
13. Rico-Bautista, E., Greenhalgh, C. J., Tollet-Egnell, P., Hilton, D. J., Alexander, W. S., Norstedt, G., and Flores-Morales, A. (2005) Suppressor of cytokine signaling-2 deficiency induces molecular and metabolic changes that partially overlap with growth hormone-dependent effects. Mol. Endocrinol. 19, 781-793 (Pubitemid 40349448)
14. Metcalf, D., Greenhalgh, C. J., Viney, E., Willson, T. A., Starr, R., Nicola, N. A., Hilton, D. J., and Alexander, W. S. (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405, 1069-1073 (Pubitemid 30447793)
15. Fan, Y., Menon, R. K., Cohen, P., Hwang, D., Clemens, T., DiGirolamo, D. J., Kopchick, J. J., Le Roith, D., Trucco, M., and Sperling, M. A. (2009) Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J. Biol. Chem. 284, 19937-19944
16. Vesterlund, M., Zadjali, F., Persson, T., Nielsen, M. L., Kessler, B. M., Norstedt, G., and Flores-Morales, A. (2011) The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels. PLoS One 6, e25358
17. Harris, J., Stanford, P. M., Sutherland, K., Oakes, S. R., Naylor, M. J., Robertson, F. G., Blazek, K. D., Kazlauskas, M., Hilton, H. N., Wittlin, S., Alexander, W. S., Lindeman, G. J., Visvader, J. E., and Ormandy, C. J. (2006) Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol. Endocrinol. 20, 1177-1187
18. Hu, J., Winqvist, O., Flores-Morales, A., Wikstrom, A. C., and Norstedt, G. (2009) SOCS2 influences LPS induced human monocyte-derived dendritic cell maturation. PLoS One 4, e7178
19. Knosp, C. A., Carroll, H. P., Elliott, J., Saunders, S. P., Nel, H. J., Amu, S., Pratt, J. C., Spence, S., Doran, E., Cooke, N., Jackson, R., Swift, J., Fitzgerald, D. C., Heaney, L. G., Fallon, P. G., Kissenpfennig, A., and Johnston, J. A. (2011) SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses. J. Exp. Med. 208, 1523-1531
20. Goodpaster, B. H., Theriault, R., Watkins, S. C., and Kelley, D. E. (2000) Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 49, 467-472 (Pubitemid 30196572)
21. Parini, P., Johansson, L., Broijersen, A., Angelin, B., and Rudling, M. (2006) Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur. J. Clin. Invest. 36, 98-104
22. Li, X., Catalina, F., Grundy, S. M., and Patel, S. (1996) Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J. Lipid Res. 37, 210-220
23. Emanuelli, B., Macotela, Y., Boucher, J., and Ronald Kahn, C. (2008) SOCS-1 deficiency does not prevent diet-induced insulin resistance. Biochem. Biophys. Res. Commun. 377, 447-452
24. Starr, R., Metcalf, D., Elefanty, A. G., Brysha, M., Willson, T. A., Nicola, N. A., Hilton, D. J., and Alexander, W. S. (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. U. S. A. 95, 14395-14399 (Pubitemid 28549378)
25. Takahashi, Y., Iida, K., Takahashi, K., Yoshioka, S., Fukuoka, H., Takeno, R., Imanaka, M., Nishizawa, H., Takahashi, M., Seo, Y., Hayashi, Y., Kondo, T., Okimura, Y., Kaji, H., Kitazawa, R., Kitazawa, S., and Chihara, K. (2007) Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 132, 938-943 (Pubitemid 46454267)
26. Sos, B. C., Harris, C., Nordstrom, S. M., Tran, J. L., Balazs, M., Caplazi, P., Febbraio, M., Applegate, M. A., Wagner, K. U., and Weiss, E. J. (2011) Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J. Clin. Invest. 121, 1412-1423
27. Machado, F. S., Johndrow, J. E., Esper, L., Dias, A., Bafica, A., Serhan, C. N., and Aliberti, J. (2006) Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12, 330-334 (Pubitemid 43355082)
28. Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., and Shoelson, S. E. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183-190 (Pubitemid 40321354)
29. Takala, J., Ruokonen, E., Webster, N. R., Nielsen, M. S., Zandstra, D. F., Vundelinckx, G., and Hinds, C. J. (1999) Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785-792 (Pubitemid 29420473)
30. Seppala-Lindroos, A., Vehkavaara, S., Hakkinen, A. M., Goto, T., Westerbacka, J., Sovijarvi, A., Halavaara, J., and Yki-Jarvinen, H. (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87, 3023-3028 (Pubitemid 34816338)
31. Martinez-Clemente, M., Ferre, N., Gonzalez-Periz, A., Lopez-Parra, M., Horrillo, R., Titos, E., Moran-Salvador, E., Miquel, R., Arroyo, V., Funk, C. D., and Claria, J. (2010) 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemiaprone ApoE-null mice. Hepatology 51, 817-827
32. Schattenberg, J. M., Singh, R., Wang, Y., Lefkowitch, J. H., Rigoli, R. M., Scherer, P. E., and Czaja, M. J. (2006) JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43, 163-172 (Pubitemid 43733603)
33. Festa, A., D'Agostino, R., Jr., Tracy, R. P., Haffner, S. M., and Insulin Resistance Atherosclerosis, S. (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51, 1131-1137 (Pubitemid 34438360)
34. Yu, X. X., Murray, S. F., Pandey, S. K., Booten, S. L., Bao, D., Song, X. Z., Kelly, S., Chen, S., McKay, R., Monia, B. P., and Bhanot, S. (2005) Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42, 362-371 (Pubitemid 41061089)